Consistent with the findings of the preclinical study using silibinin, silencing of ZEB1 restored miR‐200c expression in GRP tumor model in our study, along with reduced tumor incidence and slower tumor growth in vivo. The gene discussed is ZEB1; the disease is neoplasm.